Company intelligence / Profile preview

Cicero Diagnostics

Huntington Beach, California, United States

Ownership: Private
Development stage: Other

Overview

More than 700 U.S. reproductive endocrinologists (representing 80% of U.S. fertility centers) use ReceptivaDx, which shows a 5-fold increase in live birth rates when underlying uterine inflammation/endometriosis is detected and treated. Results from published studies and large real-world datasets demonstrate the test's clinical validity as a predictor of poor IVF outcomes due to endometrial inflammation, and as a non-invasive alternative to laparoscopy for diagnosis[1][2][3].

Therapeutic areas: Women's Health
Modalities: DeviceDiagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

Wake Forest Health Sciences (NIH-funded studies)[2]University of North Carolina (NIH-funded studies)[2]Stanford University (NIH-funded studies)[2]

Beyond the preview

Go deeper on Cicero Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cicero Diagnostics.

Explore the full profile